COVID-19

Study strongly supports the CDC’s guidance that booster shots are appropriate for anyone ages 16 and older, and that mRNA vaccines are preferred.

A single shot protects for up to 6 months against breakthrough infections, hospitalizations, and intensive care unit admissions, Johnson & Johnson says.

Out of the 3959 who were a part of the study, 2403 of the individuals were vaccinated and 1556 were unvaccinated.

The recommendations include full immunization, including third doses and/or any approved boosters.

Results of a separate analysis demonstrate that Johnson & Johnson’s booster generated a 41-fold increase in neutralizing antibodies and a 5-fold increase in T-cells against omicron.

A panel of doctors explains whether or not someone can get a different COVID-19 booster from their original vaccinations and how they compare.

Experts discuss who is eligible for COVID-19 booster shots and the misinformation around COVID-19 vaccinations.

In laboratory molecular tests, scientists mix samples with assay reagents in a highly controlled process, but because the reaction conditions are tightly controlled, the tests are both sensitive and selective, according to the researchers.

Tixagevimab co-packaged with cilgavimab is one of the only 2 antibody therapies issued emergency use authorization by the FDA that showed neutralizing activity against omicron and all other variants of concern.

The results of an analysis from investigators from Baylor College of Medicine suggest that supplementation with GlyNAC might be beneficial to those who have the virus.

The study analyzed blood samples taken from individuals infected with COVID-19, those who had been vaccinated with a 2-dose schedule and a third booster dose, and those who had reported previous infection from other COVID-19 variants of concern.

The existing EUA was also amended to reduce the time for booster dose administration from a minimum of 6 months to at least 5 months following completion of the primary COVID-19 vaccine series.

Angela Rasmussen, PhD, and Donald Alcendor, PhD have a conversation on the recent expansion of COVID-19 booster shot usage in eligible populations.

Key opinion leaders debate on the necessity of COVID-19 booster shots.

The FDA has granted emergency use authorization for a COVID-19 at-home test (Roche) and a rapid COVID-19 antigen self-test (Clinitest; Siemens Healthineers).

Individuals receiving the therapy had an 87% reduction in risk for the composite primary endpoint of virus-related hospitalization or all-cause death by day 28.

The study authors sought to determine the proportion of states that elected to follow CDC recommendations by identifying each state’s COVID-19 vaccination webpage through keyword-based internet search and set out to identify information about vaccinations for patients with cancer.

According to a Kaiser Permanente research study, individuals who received COVID-19 vaccination had lower non-COVID-19 death rates than individuals who were unvaccinated.

Laura Lee Hall, PhD, president of the Center for Sustainable Health Care Quality and Equity (SHC), addresses how the diabetes DRIVE program compares with the SHC DRIVE models for flu and COVID-19 vaccinations.

Study indicates those who experienced a greater amount of stress from the COVID-19 pandemic had reduced information processing speed.

Dr Jason Gallagher explains how COVID-19 booster shots affect herd immunity in the United States.

A panel of experts gives an overview on the purpose of COVID-19 booster shots and their critical importance to population health.

Ronald T. Piervincenzi, PhD, CEO of US Pharmacopeia, explains how pharmacists and USP came together in 2021 to work harder than ever before, as well as what can be done now to prepare for the next health crisis.

Immunocompromised individuals are at a higher risk of developing severe symptoms and dying from COVID-19.

Ronald T. Piervincenzi, PhD, CEO of US Pharmacopeia, discusses the challenges that lie ahead as we move into the third year of the COVID-19 pandemic, as well as other major developments on the horizon for pharmacists in 2022.